Ra Capital Management, L.P. Purchases 20,824 Shares of Artiva Biotherapeutics (NASDAQ:ARTV) Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Director Ra Capital Management, L.P. acquired 20,824 shares of Artiva Biotherapeutics stock in a transaction dated Wednesday, July 29th. The shares were bought at an average price of $9.99 per share, for a total transaction of $208,031.76. Following the transaction, the director owned 17,304,626 shares of the company’s stock, valued at approximately $172,873,213.74. The trade was a 0.12% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Friday, July 31st, Ra Capital Management, L.P. bought 24,944 shares of Artiva Biotherapeutics stock. The shares were bought at an average price of $9.93 per share, with a total value of $247,693.92.
• On Friday, July 24th, Ra Capital Management, L.P. purchased 41,319 shares of Artiva Biotherapeutics stock. The stock was bought at an average price of $9.99 per share, for a total transaction of $412,776.81.
• On Thursday, July 23rd, Ra Capital Management, L.P. purchased 59,880 shares of Artiva Biotherapeutics stock. The stock was bought at an average price of $9.96 per share, for a total transaction of $596,404.80.
• On Wednesday, July 22nd, Ra Capital Management, L.P. acquired 84,124 shares of Artiva Biotherapeutics stock. The shares were bought at an average cost of $9.93 per share, with a total value of $835,351.32.
• On Tuesday, July 21st, Ra Capital Management, L.P. bought 120,582 shares of Artiva Biotherapeutics stock. The stock was purchased at an average cost of $9.55 per share, for a total transaction of $1,151,558.10.
• On Friday, July 10th, Ra Capital Management, L.P. bought 15,102 shares of Artiva Biotherapeutics stock. The stock was purchased at an average price of $8.97 per share, for a total transaction of $135,464.94.
• On Monday, July 13th, Ra Capital Management, L.P. purchased 6,552 shares of Artiva Biotherapeutics stock. The shares were purchased at an average price of $8.94 per share, with a total value of $58,574.88.
• On Friday, June 26th, Ra Capital Management, L.P. acquired 1,876 shares of Artiva Biotherapeutics stock. The stock was purchased at an average cost of $8.98 per share, for a total transaction of $16,846.48.
• On Thursday, June 25th, Ra Capital Management, L.P. acquired 31,000 shares of Artiva Biotherapeutics stock. The shares were purchased at an average cost of $8.88 per share, for a total transaction of $275,280.00.
• On Tuesday, June 16th, Ra Capital Management, L.P. bought 124,893 shares of Artiva Biotherapeutics stock. The stock was acquired at an average cost of $8.89 per share, with a total value of $1,110,298.77.

Artiva Biotherapeutics Trading Down 3.2%

ARTV traded down $0.33 during trading hours on Friday, hitting $10.10. The company’s stock had a trading volume of 360,712 shares, compared to its average volume of 388,730. The stock has a market cap of $249.64 million, a price-to-earnings ratio of -2.85 and a beta of 2.18. The business’s 50-day moving average price is $8.96 and its 200-day moving average price is $7.49. Artiva Biotherapeutics, Inc. has a 12 month low of $2.22 and a 12 month high of $14.53.

Artiva Biotherapeutics (NASDAQ:ARTV) last issued its quarterly earnings data on Friday, May 8th. The company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07). On average, analysts forecast that Artiva Biotherapeutics, Inc. will post -2.45 earnings per share for the current year.

Institutional Trading of Artiva Biotherapeutics

Hedge funds have recently bought and sold shares of the stock. Dimensional Fund Advisors LP bought a new stake in Artiva Biotherapeutics during the 1st quarter valued at $131,000. Sanctuary Advisors LLC bought a new stake in Artiva Biotherapeutics during the first quarter valued at about $139,000. Simplify Asset Management Inc. purchased a new position in shares of Artiva Biotherapeutics in the 1st quarter worth approximately $150,000. OMERS ADMINISTRATION Corp purchased a new stake in Artiva Biotherapeutics during the fourth quarter valued at approximately $91,000. Finally, Marshall Wace LLP acquired a new stake in Artiva Biotherapeutics in the fourth quarter valued at approximately $341,000.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on ARTV. Wall Street Zen cut shares of Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, May 17th. Wedbush lifted their price target on shares of Artiva Biotherapeutics from $23.00 to $40.00 and gave the company an “outperform” rating in a research note on Monday, May 11th. Needham & Company LLC reiterated a “buy” rating and issued a $41.00 price target on shares of Artiva Biotherapeutics in a report on Monday, June 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Tuesday, July 21st. Finally, HC Wainwright raised their price objective on Artiva Biotherapeutics from $15.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, May 8th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $39.00.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.